New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2012
08:10 EDTITMNInterMune a top 2012 pick, says Brean Murray
Brean Murray said negative macro and company specific catalysts created a buying opportunity for InterMune. The firm called it a top pick for 2012 citing valuation, implications for strong German demand of Esbriet, and the orphan drug status of the drug. Shares are Buy rated with a $42 price target.
News For ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:11 EDTITMNRoche sees completing InterMune acquisition later today
Subscribe for More Information
September 22, 2014
13:53 EDTITMNRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
September 20, 2014
15:43 EDTITMNInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use